Monoclonal Antibody Therapy Compared With No Further Therapy After Surgery in Treating Patients With Stage II Colon Cancer

This study has been completed.

Study NCT00002968 Information provided by Cancer and Leukemia Group B

First Received: November 1, 1999 Last Updated: August 3, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	June 2010
Primary Completion Date:	July 2003 (Final data collection date for primary outcome measure)

Publications:

Bertagnolli MM, Niedzwiecki D, Hall M, et al.: Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581. [Abstract] J Clin Oncol 27 (Suppl 15): A-4012, 2009.

Colacchio TA, Niedzwiecki D, Compton C, et al.: Phase III trial of adjuvant immunotherapy with MOAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581). [Abstract] J Clin Oncol 22 (Suppl 14): A-3522, 250s, 2004.